The abstract is read at the publisher; the summary is JClub's.
MethMarkerDB 2.0 expands cancer DNA methylation biomarker resources from 13 to 21 cancer types and 658 to 1236 whole-genome methylome samples, totaling ~5.6 million candidate DMRs.
- Why it matters: Cancer-associated DMRs are promising biomarkers, yet their biological meaning and practical use are not systematically clarified across datasets.
- What they did: The database integrates 450K methylation data from The Cancer Genome Atlas and Epigenome-Wide Association Study Atlas with transcript annotations, plus cell-type reference methylation and four functional analysis modules.
- The result: It enables CpG-level inspection, cellular-background checks, and links DMRs to transcription factor binding evidence and cancer cell-line drug responses, including guide RNA design for methylation-sensitive restriction enzyme-Cas assays.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.